Upstream / Downstream


Explore pathways related to this product.

To Purchase # 8406LC

8406LC 10 µg (With Carrier) $204.00.0
8406LF 10 µg (Carrier Free) $204.00.0


Find answers on our FAQs page.


PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools


Source / Purification

Recombinant human TGF-β2 (hTGF-β2) Ala303-Ser414 (Accession #NP_003229) was expressed in human 293 cells at Cell Signaling Technology.

Product Description


>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-β2. All lots are greater than 98% pure.

Molecular Formula:

Recombinant hTGF-β2 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,719. DTT-reduced protein migrates as a 12 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 24 kDa protein. The expected amino-terminal ALDAA of recombinant hTGF-β2 was verified by amino acid sequencing.


The bioactivity of recombinant hTGF-β2 was was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 0.1-0.3 ng/ml.


Less than 0.01 ng endotoxin/1 μg hTGF-β2.

Product Usage Information


With carrier: Lyophilized from a 0.22 μm filtered solution of 35% acetonitrile and 0.1% trifluoroacetic acid containing 20 μg BSA per 1 μg hTGF-β2. Carrier free: Lyophilized from a 0.22 μm filtered solution of 35% acetonitrile and 0.1% trifluoroacetic acid.

Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-β2 is produced by eosinophils, astrocytes, glioblastoma and other cancer derived cell types (1-6). TGF-β2 inhibits antigen-induced T-cell proliferation, inhibits epithelial cell proliferation, induces mesenchymal cell proliferation and has cell specific effects on apoptosis (1-8). TGF-β2 binds to TβRII and binding is promoted by TβRIII. TβRI then complexes with TβRII and TβRIII (3,5). Signaling involves phosphorylation of the SMAD proteins (2,3,9). TGF-β2 also activates Erk2, p38, and JNK pathways (9). Knockout of TGF-β2 in mice severely impacts heart, lung and eye development (10).

1.  Balzar, S. et al. (2005) J Allergy Clin Immunol 115, 110-7.

2.  Siegel, P.M. and Massagué, J. (2003) Nat Rev Cancer 3, 807-21.

3.  Bierie, B. and Moses, H.L. (2006) Nat Rev Cancer 6, 506-20.

4.  Hinz, S. et al. (2007) Cancer Res 67, 8344-50.

5.  Damstrup, L. et al. (1993) Br J Cancer 67, 1015-21.

6.  Constam, D.B. et al. (1992) J Immunol 148, 1404-10.

7.  Zhang, H. et al. (2008) Immunology 124, 304-14.

8.  Dufour, C. et al. (2008) Am J Physiol Endocrinol Metab 294, E794-801.

9.  Moustakas, A. and Heldin, C.H. (2009) Development 136, 3699-714.

10.  Dünker, N. and Krieglstein, K. (2000) Eur J Biochem 267, 6982-8.

Entrez-Gene Id 7042
Swiss-Prot Acc. P61812

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Human Transforming Growth Factor β2 (hTGF-β2)